The association between hospital capacity and survival after allogeneic bone marrow transplantation (allo-BMT) was examined using the dataset accumulated by the Japan Society of Hematopoietic Cell Transplantations (JSHCT). The subjects were 3134 patients who received first allo-BMTs between 1991 and 1997 reported to the JSHCT. They were divided into three groups by cumulative hospital experience of allo-BMTs: low volume (capacity) (LV; р25 cases), moderate volume (capacity) (MV; 26-75 cases) and high volume (capacity) (HV; у76 cases). Using a proportional hazards model, the association of hospital experience with early survival at day 100 (D100S), and overall survival (OS) were examined. For leukemia patients, leukemiafree survival (LFS) was also analyzed. When HV was defined as the reference group, the hazard ratios (HRs) of OS for all subjects were 1.10 (95% confidence interval; 0.97-1.25) for MV and 1.25 for LV (1.08-1.44). The HRs with D100S were 1.20 (0.96-1.51) for MV and 1.40 (1.08-1.80) for LV. Larger values were observed for OS and D100S in cases of leukemia. Survival after BMT from sibling donors was clearly influenced by hospital experience, but this was not the case from unrelated donors. These findings suggest that size of the transplant team should be considered in order to improve the outcome of sibling BMT in general. Bone Marrow Transplantation (2000) 26, 1061-1067. Keywords: hospital mortality; bone marrow transplantation; allogeneic transplantation; survival analysis Evaluation of hospital performance in terms of treatment outcome, especially for serious diseases requiring expensive medical technology, is very important not only for improving the health care skills of each facility, but also for planning an effective regional health care system. The idea is not new, and evaluation has already been conducted
for total hospital mortality rate, 1 and specific diseases 2 and/or treatment modes such as heart transplants 3 and other surgeries, [4] [5] [6] [7] mainly in the United States. Among hospital characteristics accumulated experience has been reported to be significant in many situations; lower mortality is generally associated with hospitals with a large capacity compared to those with limited experience. [4] [5] [6] [7] [8] [9] Strictly speaking, there are several methodological problems that interfere with the determination of the hospital performance fairly. 10 However, it is implied that studies reporting differences in outcomes and related factors are quite important.
Allogeneic bone marrow transplantation (allo-BMT) has become a common, but expensive treatment, which is effective for hematopoietic diseases, [11] [12] [13] [14] [15] and conducted in many hospitals throughout the world. In Japan, hundreds of hospitals can provide related donor BMT, because there are no legal regulations or restrictive guidelines. On the other hand, unrelated donor BMT is allowed at about 150 hospitals which are accredited by the Japan Marrow Donor Program (JMDP). According to nationwide surveys conducted by the Japan Society for Hematopoietic Cell Transplantation (JSHCT; formerly the Japan Society for Bone Marrow Transplantation), approximately 5000 allo-BMTs, including pediatric transplants, were performed at about 300 hospitals between 1991 and 1997 in Japan. 16 This number is next in rank to those registered by the International Bone Marrow Transplantation Registry (IBMTR) and by the European Group of Blood and Marrow Transplantation (EBMT).
To our knowledge, two studies were conducted concerning this issue about allo-BMT; one from the EBMT 17 and the other from the IBMTR. 18 The latter reported a positive association between hospital experience and post-transplant outcome for HLA-identical sibling BMT, 18 while the former showed no association. 17 This paper examines the association for adult allo-BMT, including unrelated donor BMT, using the data from JSHCT, the third largest registry.
Patients and methods

Data source
Transplant data were obtained from the JSHCT dataset, which consisted of two files; one from the pediatric hema-tology group and the other from the hematology group for adult patients. Data collection for pediatric transplants started in 1983 as a nationwide survey of the Bone Marrow Transplantation Committee of the Japan Society for Pediatric Hematology. Since then, the nationwide survey has been conducted annually. 19 Annual nationwide surveys for adult transplants began in 1993 under the auspices of the JSHCT. Subjects of the first survey for adult transplants were patients who underwent stem cell transplantation between July 1990 and June 1993. Accordingly, data for adult transplants conducted in and after July 1990 have been accumulated by the JSHCT. In 1998, the file for pediatric transplants was incorporated under the management of the Office of Nationwide Surveys (Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya) of the JSHCT. 16 Both surveys cover all types of hematopoietic cell transplantation including unrelated donor BMT, related donor BMT and allogeneic PBSCT (peripheral blood stem cell transplantation), autologous BMT and PBSCT, and umbilical stem cell transplantation. At present, the total number of transplant teams participating in the surveys are 271 in total; 112 from pediatrics departments, 124 from internal medicine departments, one from a surgery department, six from gynaecology departments, 14 from urology departments, and 14 from other departments. The data analyzed in this paper were from the file for adult transplants. HLA-matching has been undertaken for phenotype and genotype separately since the 1996 survey. Prior to 1996, it is not clear whether HLA matching for related donor BMT was determined phenotypically or genotypically, although the great majority of HLA matching seems to have been based on phenotype. In the present analyses, reported data, whether based on phenotype or genotype, were adopted for the definition of HLA matching. All cases of unrelated donor BMT were serologically HLA-A, -B, and -DR matched. Since genotyping was introduced for searching for unrelated HLA-matched donors through the JMDP, 20 the matching is almost always evaluated genotypically (HLA-A, -B, and -DR) for unrelated donor BMTs.
Statistical analysis
To examine the influence of transplant experience, teams were divided into three categories in terms of their total number of allo-BMT cases, high (HV; у76 cases), moderate (MV; 26-75 cases) and low (LV; р25 cases). The outcome was measured in terms of overall survival (OS) and day 100 survival (D100S). Furthermore, leukemia-free survival (LFS) was evaluated in leukemia patients. All analyses were performed by STATA. 21 A chi-square test was employed to examine independence between two categorical variables. Survival curves for D100S, OS and LFS were estimated by the Kaplan-Meier method 22 and differences in survival were assessed by the logrank test. Multivariate analyses for D100S, OS and LFS were conducted with a proportional hazards model. 23 Factors used for the multivariate analysis were as follows: hospital experience group (HV, MV and LV), age at transplant (у40 years and Ͻ40 years), year of transplant, donor (sibling, non-sibling relative and unrelated), sex, HLA matching status (matched and mismatched), conditioning (TBI-containing regimen, BU/CY and others), GVHD prophylaxis (short-term methotrexate plus cyclosporine (sMTX/CYA), short-term methotrexate plus FK506 (sMTX/FK506) and others), and diagnosis of recipient (standard risk leukemia (AL in first complete remission and CML in first chronic phase), high risk leukemia (advanced stage of leukemia than standard risk), MDS, ML, SAA and other diseases).
Results
Characteristics of patients in the three hospital categories (HV, MV and LV) are summarized in Table 1 . Types of disease showed no significant difference among hospital groups, while types of donor were significantly different (P Ͻ 0.001). BMTs from unrelated donors were mainly conducted at HV or MV hospitals, because experience of a defined number of related donor BMTs was required for accreditation by the JMDP. Accordingly, most BMTs conducted at LV hospitals were from HLA-matched sibling donors. HLA-matching status did not differ among HV, MV and LV; 93.6%, 94.6% and 95.1% for sibling donor BMTs, and 75.9%, 73.6% and 65.1% for unrelated donor BMTs, respectively.
Concerning pre-transplant conditioning, TBI containing regimens were common and the use of BU/CY regimens was relatively more frequent in the LV group than in the HV and MV groups, although the HV group included 10.4% 'unknown' cases. For GVHD prophylaxis, sMTX/CYA was most commonly used in all groups. Prophylaxis with sMTX/FK506 was more frequent in the HV group than in the MV and LV groups. Figure 1 shows survival curves of OS after HLAmatched BMTs for all diseases according to group size. A statistically significant difference was found in sibling donor BMTs (P = 0.026), but not in BMTs from all donors and unrelated donors.
Adjusted hazard ratios with 95% confidence intervals for all patients are shown in Table 2 . As for OS, hazard ratios for MV and LV were larger than unity: 1.10 (95% confiBone Marrow Transplantation in survival was observed in unrelated BMTs among the three groups. Subgroup analyses were conducted for each disease. Table 3 shows adjusted hazard ratios for D100S, LFS, and OS for leukemia cases, which constituted 76.7% of the subjects (2403 cases). The estimated hazard ratios for all donors were larger than those estimated for all diseases in Table 2 . The hazard ratios for LFS were statistically significant, 1.23 (1.07-1.47) for MV and 1.27 (1.08-1.50) for LV, which were close to the OS estimates. Inconsistent results were observed for D100S, LFS, and OS between sibling donor and unrelated donor BMTs. The LV and/or MV groups had a significantly worse prognosis with transplants from sibling donors. Hazard ratios for D100S were 1.78 (1.17-2.74) for MV and 1.77 (1.11-2.81) for LV. ure 2a shows LFS curves after BMT from matched sibling donors. The difference was statistically significant (P = 0.0043). There was no difference in LFS after BMT from unrelated donors among the three groups (Figure 2b ). Hazard ratios for MDS, ML and SAA are shown in Table  4 . The numbers of subjects were 256, 144 and 195, respectively. Statistically significant differences were not observed, and because of the relatively small numbers of cases, further subgroup analyses by donor type were not carried out.
Discussion
We investigated whether hospital capacity could be a factor affecting treatment outcome of allo-BMT. Number of allo- Adjusted for age, year of transplant, donor, sex, HLA matching status, conditioning regimen, GVHD prophylaxis regimen, and disease.
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BMTs undertaken was found to affect overall survival and day 100 survival for all subjects, even after taking into account age, sex, year of transplant, donor type, HLA matching status, conditioning regimen, GVHD prophylaxis regimen, and underlying disease. Subgroup analyses showed that survival of leukemia patients transplanted from sibling donors was significantly affected by hospital experience. Leukemia-free survival was also favorably influenced in the HV hospital group. In the analyses for SAA, ML, and MDS, however, there was no statistically significant association between different hospital capacities.
To date, two studies have been reported concerning the association between hospital capacity and post-transplant outcome. 17, 18 The first was conducted by the EMBT, which examined the prognosis for HLA-matched sibling BMT in AML, ALL and CML according to hospital size. No statistically significant difference was observed for LFS, transplant-related mortality (TRM) and relapse. The second was conducted by the IBMTR for AML and ALL in first remission and CML in first chronic phase, transplanted from an HLA-matched sibling. They reported that TRM was moderately higher in the centers with five or less cases annually. Our subjects received BMTs from unrelated donors and HLA-mismatched siblings for leukemia and other diseases. More transplant-related factors were taken into account on multivariate analyses. Categorization by hospital size might be a significant explanation for the inconsistency among the three studies, although our criteria were similar to the EBMT study which reported no association.
In the present study, there are several possible explanations for the higher survival rates in HV hospitals, after sibling donor BMT for leukemia. First, differences in disease severity and treatment modality must be considered. Since possible factors including age, sex, year of transplant, HLA matching status, conditioning regimen, GVHD prophylaxis were adjusted for these analyses, their possible influence was excluded. Second, higher survival rates may simply reflect better quality of general hospital care. The high capacity hospitals tend to be regional center hospitals, where facilities are well organized and medical staff are well trained. Such variables are usually difficult to adjust. Lastly, experience of the specific disease in each hospital might have truly contributed to the improved prognosis.
The difference in survival was not observed among BMTs from unrelated donors, despite an increased risk of transplant-related complications such as acute GVHD 24, 25 and opportunistic infections. Management of such critical events would be expected to require special skills based on experience, but the present data did not indicate any importance of high capacity. When patients receiving HLAmatched donor BMTs were analyzed separately, a similar result was obtained. The heterogeneous effect of hospital size is of interest. In this analysis, 74 hospitals conducted unrelated donor BMT and these were selected by accreditation with the JMDP. The reasons for the different BMT outcomes according to hospital size remain to be clarified, but it is possible that hospital selection reduced differences due to amount of experience.
Additional comments are necessary to interpret and extrapolate our results to patient populations other than those of this analysis. First, cover of the JSHCT annual survey is not monitored for completeness with allo-BMTs from related donors, but 78.4% of unrelated donor BMTs were reported by record linkage with the JMDP. If the prognosis of sibling donor BMTs at unreporting LV hospitals were worse than that at reporting LV hospitals, the difference would be larger, and conversely if better it would be smaller. Second, analyses were based on BMTs which were performed between 1991 and 1997, and followed until July 1999. The treatment skills and background environment for allo-BMT have improved recently, which may influence treatment outcome and survival among hospitals. Third, limitations of adjustment for prognostic factors must be considered. Prognostic factors other than those included in the present analyses could modify the results from our dataset.
In Japan, allo-BMT was started in 1974, and in the early days were mostly from HLA-identical siblings. Currently, approximately 1000 child and adult patients receive allo-BMT annually, 16 at over 300 institutions in Japan. Unrelated donor BMT was started in 1989 with donors recruited by a local marrow donor program, the Tokai Marrow Donor Bank, 25 and the JMDP has been covering the entire country since 1992. The cumulative number of unrelated donor BMTs exceeded 2500 in February 2000, and unrelated donor BMTs mediated by the JMDP has been established as an alternative to related donor BMTs for the treatment of leukemia and SAA. 20, 26 All unrelated donor BMTs are performed in institutions accredited by the JMDP, based on the criterion that 15 related donor BMTs have been conducted over the past 3 years.
In conclusion, the data accumulated by the JSHCT showed differences in survival after sibling donor BMT among hospital groups with different amounts of experience. Our findings suggest that a system similar to the hospital accreditation for unrelated donor BMT may be desirable to improve treatment outcome of sibling donor BMTs overall.
